- Home
- LU vs MIRM Comparison
LU vs MIRM Comparison
Compare LU & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- MIRM
- Stock Information
- Founded
- LU 2005
- MIRM 2018
- Country
- LU China
- MIRM United States
- Employees
- LU N/A
- MIRM N/A
- Industry
- LU Finance: Consumer Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- MIRM Health Care
- Exchange
- LU Nasdaq
- MIRM Nasdaq
- Market Cap
- LU 2.4B
- MIRM 2.1B
- IPO Year
- LU 2020
- MIRM 2019
- Fundamental
- Price
- LU $2.53
- MIRM $46.95
- Analyst Decision
- LU Hold
- MIRM Strong Buy
- Analyst Count
- LU 2
- MIRM 11
- Target Price
- LU $2.98
- MIRM $57.00
- AVG Volume (30 Days)
- LU 2.3M
- MIRM 450.2K
- Earning Date
- LU 10-21-2024
- MIRM 02-26-2025
- Dividend Yield
- LU N/A
- MIRM N/A
- EPS Growth
- LU N/A
- MIRM N/A
- EPS
- LU N/A
- MIRM N/A
- Revenue
- LU $4,671,260,668.00
- MIRM $307,028,000.00
- Revenue This Year
- LU N/A
- MIRM $82.14
- Revenue Next Year
- LU $1.48
- MIRM $26.18
- P/E Ratio
- LU N/A
- MIRM N/A
- Revenue Growth
- LU N/A
- MIRM 112.14
- 52 Week Low
- LU $2.00
- MIRM $23.14
- 52 Week High
- LU $4.94
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- LU 55.24
- MIRM 65.98
- Support Level
- LU $2.30
- MIRM $40.55
- Resistance Level
- LU $2.52
- MIRM $47.25
- Average True Range (ATR)
- LU 0.10
- MIRM 1.49
- MACD
- LU 0.02
- MIRM 0.56
- Stochastic Oscillator
- LU 70.31
- MIRM 95.52
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.